Pearce IP BioBlast w/e 22 March 2024
22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22 March 2024, the first case management hearing was held before Justice Nicholas in the Federal Court of Australia, Sydney, in...
Pearce IP BioBlast w/e 15 March 2024
15 MAR 2024 | AU | November 2023 PBAC Public Summary Documents Feature Biopharma On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions...
Pearce IP BioBlast w/e 8 March 2024
9 MAR 2024 US | Samsung Bioepis Presents Interchangeability Updates for its Adalimumab and Ustekinumab Biosimilars at AAD On 9 March 2024, Samsung Bioepis presented two papers of study results for its immunology portfolio at the 2024 American...
Pearce IP BioBlast w/e 4 March 2024
1 MAR 2024 | AU | Authorities raid Como Compounding Pharmacy in Melbourne and Seize Semaglutide The Australian Financial Review reported that on 1 March 2024 TGA investigators raided Como Compounding Pharmacy in Melbourne and seized ‘off-brand’...
Pearce IP BioBlast w/e 23 Feb 2024
23 FEB 2024 | EU | Samsung Bioepis Presented Study Results for ustekinumab SB17, Biosimilar to Janssen’s Stelara®, at ECCO On 23 February 2024, Samsung Bioepis presented two new study results for ustekinumab SB17 (biosimilar to Janssen’s...
Pearce IP BioBlast w/e 16 Feb 2024
19 JAN 2024 | AU | March a Bumper Month for Biopharma at the Pharmaceutical Benefits Assessment Committee (PBAC) in Australia According to the Pharmaceutical Benefits Assessment Committee (PBAC) agenda for March 2024, published on 5 January...
Pearce IP BioBlast w/e 09 Feb 2024
09 FEB 2024 | AU | Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab and Bevacizumab Biosimilars On 9 February 2024, Biocon Biologics (Biocon) announced that it has signed a five-year exclusive...
Pearce IP BioBlast w/e 02 Feb 2024
2 FEB 2024 | EU | US | Regeneron’s linvoseltamab MAA Filing Accepted by EMA; BLA Submitted to FDA for Multiple Myeloma Regeneron announced that its marketing authorisation application (MAA) for linvoseltamab to treat adult patients with...
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
natalizumab | Tysabri® | Biogen/Elan
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | Merck
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
Meet our BioBlast™ authors
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.